Advancing Medical Diagnostics: Rapid, Label-Free Detection and Differentiation of Shiga Toxin Variants in Human Serum Using a Cost-Effective PCA-Assisted SERS Platform. [PDF]
Milano A +12 more
europepmc +1 more source
Detonating a "time bomb": how enteric infection stress triggers prophage induction in commensal microbiota and exacerbates disease progression. [PDF]
Yang L, Xu Y, Wang X.
europepmc +1 more source
Related searches:
Affinity purification of Shiga-like toxin I and Shiga-like toxin II
Journal of Microbiological Methods, 1998Abstract A facile method is described for affinity purifying Shiga-like toxin I (verotoxin 1) or Shiga-like toxin II (verotoxin 2) from cell-free Escherichia coli culture supernatant solutions using immobilized synthetic analogs of the digalactoside [αGal(1,4)βGal] host cell receptor for these toxins.
George L Mulvey, Glen D Armstrong
exaly +2 more sources
Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells
Microbes and Infection, 2001Shigella dysenteriae and Shiga-toxin-producing Escherichia coli (STEC) elaborate the AB holotoxins, Shiga or Shiga-like toxins (Stx). Stx play a major role in the pathogenesis of haemorrhagic colitis and haemolytic uremic syndrome. This review provides an overview of the mechanisms of action of Stx and a model of the pathogenesis of Stx-induced disease.
Roy Robins-Browne, E V O'Loughlin
exaly +3 more sources
Inhibition Of Shiga-Like Toxins By Brefeldin A
Journal of Infectious Diseases, 1995The effects of Shiga-like toxins on the morphology and protein synthetic capability of HeLa cells in tissue culture could be prevented by brefeldin A, an inhibitor of certain intracellular Golgi functions. Brefeldin A was without effect on the binding of Shiga-like toxin to cells.
S T, Donta +2 more
openaire +2 more sources
The use of Shiga-like toxin 1 in cancer therapy
Critical Reviews in Oncology/Hematology, 2001The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1, SLT-I, Verotoxin 1, VT1) targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. The frequent occurrence of SLT-1 receptors on tumor cells derived from patients with hematological cancers (follicular lymphoma, multiple myeloma, chronic lymphocytic leukemia ...
Jean Gariépy
exaly +3 more sources
DNA probes for Shiga-like toxins I and II and for toxin-converting bacteriophages
Journal of Clinical Microbiology, 1988A set of DNA probes has been developed to study the genes for Shiga-like toxins (SLT) and the bacteriophage from which these toxin genes were isolated. Under stringent conditions of hybridization (80 to 90% homology), these probes detect strains containing (i) SLT I-related genes, (ii) SLT II-related genes, (iii) phage sequences from the SLT I ...
J W, Newland, R J, Neill
openaire +2 more sources
AbstractShiga toxin and the related Shiga‐like toxins (SLT), produced by Escherichia coli, can cause hemorrhagic colitis and hemolytic uremic syndrome (HUS). Human intravenous immune globulin (HIVIg) blocks the cytotoxicity of some SLTs in vitro. To examine the ability of HIVIg to modify disease caused by Shiga‐like toxin I or Shiga‐like toxin II (SLT ...
P L, Havens, W M, Dunne, E M, Burd
openaire +2 more sources
Effect of verocytotoxins (Shiga-like toxins) on human neutrophils in vitro
Pediatric Nephrology, 2005Neutrophil activation occurs in diarrhoea-associated HUS and correlates with disease severity, implying a role in pathogenesis. Verocytotoxin (Shiga-like toxin) has been shown to stimulate endothelium to release chemokines and express leukocyte adhesion molecules that would lead to indirect neutrophil-endothelial interaction.
Julie U, Holle +4 more
openaire +2 more sources
Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands
Nature, 2000The diseases caused by Shiga and cholera toxins account for the loss of millions of lives each year. Both belong to the clinically significant subset of bacterial AB5 toxins consisting of an enzymatically active A subunit that gains entry to susceptible mammalian cells after oligosaccharide recognition by the B5 homopentamer. Therapies might target the
P I, Kitov +7 more
openaire +2 more sources

